BCBrett S. Carver

Brett S. Carver

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brett S. Carver has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figure S1 from Targeting Tumor Microenvironment–Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer

    by Brian M. Shinder, Young Sun Lee, Ninghui Mao, Nazifa Salsabeel, Zeda Zhang, Harmanpreet Kaur, Xiaoping Chen, Qing Chang, Elisa de Stanchina, Anuradha Gopalan, et al.

    Supplementary Figure S1 shows validation studies for the impact of PTEN loss on the NRG1 phenotype.

  • Open Access

    Supplementary Figure S2 from Targeting Tumor Microenvironment–Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer

    by Brian M. Shinder, Young Sun Lee, Ninghui Mao, Nazifa Salsabeel, Zeda Zhang, Harmanpreet Kaur, Xiaoping Chen, Qing Chang, Elisa de Stanchina, Anuradha Gopalan, et al.

    Supplementary Figure S2 shows the impact of NRG1 and HER2/3 inhibition on PTEN-loss prostate cancer in vivo.

  • Open Access

    Data from Targeting Tumor Microenvironment–Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer

    by Brian M. Shinder, Young Sun Lee, Ninghui Mao, Nazifa Salsabeel, Zeda Zhang, Harmanpreet Kaur, Xiaoping Chen, Qing Chang, Elisa de Stanchina, Anuradha Gopalan, et al.

    Investigating the mechanisms of acquired resistance to antiandrogens remains a critical clinical need as patients with prostate cancer inevitably develop resistance to androgen receptor (AR)–targeted therapies. Previously, we demonstrated that neuregulin 1 (NRG1) derived from cancer-associated fibroblasts (CAF) promotes antiandrogen resistance through human epidermal growth factor receptor 3 (HER3)–AKT signaling. In this study, we sought to further dissect the molecular context in which NRG1-induced PI3K signaling activation plays a dominant role in driving resistance and evaluate whether targeting HER2/3 dimerization can influence sensitivity to AR inhibition. IHC analysis of radical prostatectomy specimens from patients with prostate cancer treated with or without neoadjuvant hormonal therapy shows that NRG1 was significantly upregulated following AR inhibition, independent of PTEN status. However, we found that stimulation with recombinant NRG1 or CAF-conditioned media induced resistance to AR inhibition only in PTEN wild-type prostate cancer cells and not in PTEN-deficient cells. Selective inhibition of NRG1 using the clinical-grade bispecific humanized immunoglobulin G1, zenocutuzumab (Zeno, MCLA-128), restored sensitivity to AR-targeted therapies in PTEN wild-type tumors, demonstrating its efficacy as a potential therapeutic agent to block the effects of NRG1. In the context of PTEN loss and AR inhibitor resistance, Zeno did not restore sensitivity. These findings highlight the critical molecular context in which tumor microenvironment–derived NRG1 affects responsiveness to AR inhibition and suggest that targeting NRG1 is a promising strategy for overcoming resistance to androgen blockade in PTEN wild-type prostate cancers.

  • Open Access

    Targeting Tumor Microenvironment–Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer

    by Brian M. Shinder, Young Sun Lee, Ninghui Mao, Nazifa Salsabeel, Zeda Zhang, Harmanpreet Kaur, Xiaoping Chen, Qing Chang, Elisa de Stanchina, Anuradha Gopalan, et al.

    Investigating the mechanisms of acquired resistance to antiandrogens remains a critical clinical need as patients with prostate cancer inevitably develop resistance to androgen receptor (AR)–targeted therapies. Previously, we demonstrated that neuregulin 1 (NRG1) derived from cancer-associated fibroblasts (CAF) promotes antiandrogen resistance through human epidermal growth factor receptor 3 (HER3)–AKT signaling. In this study, we sought to further dissect the molecular context in which NRG1-induced PI3K signaling activation plays a dominant role in driving resistance and evaluate whether targeting HER2/3 dimerization can influence sensitivity to AR inhibition. IHC analysis of radical prostatectomy specimens from patients with prostate cancer treated with or without neoadjuvant hormonal therapy shows that NRG1 was significantly upregulated following AR inhibition, independent of PTEN status. However, we found that stimulation with recombinant NRG1 or CAF-conditioned media induced resistance to AR inhibition only in PTEN wild-type prostate cancer cells and not in PTEN-deficient cells. Selective inhibition of NRG1 using the clinical-grade bispecific humanized immunoglobulin G1, zenocutuzumab (Zeno, MCLA-128), restored sensitivity to AR-targeted therapies in PTEN wild-type tumors, demonstrating its efficacy as a potential therapeutic agent to block the effects of NRG1. In the context of PTEN loss and AR inhibitor resistance, Zeno did not restore sensitivity. These findings highlight the critical molecular context in which tumor microenvironment–derived NRG1 affects responsiveness to AR inhibition and suggest that targeting NRG1 is a promising strategy for overcoming resistance to androgen blockade in PTEN wild-type prostate cancers.


  • Open Access

    ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L

    by Weiran Feng, Erik Ladewig, Matthew Lange, Nazifa Salsabeel, Huiyong Zhao, Young Sun Lee, Anuradha Gopalan, Hanzhi Luo, Wenfei Kang, Ning Fan, et al.

    Despite the high prevalence of ERG transcription factor translocations in prostate cancer, the mechanism of tumorigenicity remains poorly understood. Using lineage tracing, we find the tumor-initiating activity of ERG resides in a subpopulation of murine basal cells that coexpress luminal genes (BasalLum) and not in the larger population of ERG+ luminal cells. Upon ERG activation, BasalLum cells give rise to highly proliferative intermediate (IM) cells with stem-like features that coexpress basal, luminal, hillock and club marker genes, before transitioning to Krt8+ luminal cells. Transcriptomic analysis of ERG+ human prostate cancers confirms the presence of rare ERG+ BasalLum cells, as well as IM cells whose presence is associated with a worse prognosis. Single-cell analysis revealed a chromatin state in ERG+ IM cells enriched for STAT3 transcription factor binding sites and elevated expression of the KMT2A/MLL1 and DOT1L, all three of which are essential for ERG-driven tumorigenicity in vivo. In addition to providing translational opportunities, this work illustrates how single-cell approaches combined with lineage tracing can identify cancer vulnerabilities not evident from bulk analysis.


  • Open Access

    Uncoupling of Akt and mTOR signaling drives resistance to Akt inhibition in PTEN loss prostate cancers

    by Ninghui Mao, Young Sun Lee, Nazifa Salsabeel, Zeda Zhang, Dan Li, Harmanpreet Kaur, Xiaoping Chen, Qing Chang, Sanjay Mehta, Jesse Barnes, et al.

    Recent phase 3 clinical trial showed improved radiographic progression-free survival in PTEN-deficient prostate cancers treated with combined Akt and AR inhibition. Building on this and our previous research into PI3K and AR signaling interactions, we aimed to define the mechanisms of response and resistance to Akt inhibition. We discovered that restoration of mTOR signaling was the early dominant driver of resistance to Akt inhibition. Mechanistically, this can be achieved through molecular alterations, resulting in loss of negative regulators of mTOR. Unexpectedly, we discovered that this was dominated by restoration of mTOR signaling through the nutrient sensing arm. This can be achieved by loss of the components of the GATOR/KICSTOR complexes or through cellular processes, leading to the recycling of amino acids. The addition of an mTOR inhibitor restored sensitivity to Akt inhibition and represents a precision-based strategy to overcome resistance in the clinic.


  • Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease

    by Jack P. Gleeson, Andrea Knezevic, Maria Bromberg, Sujata Patil, Joel Sheinfeld, Brett S. Carver, Manjit Bains, David R. Jones, Dean F. Bajorin, George J. Bosl, et al.

    PURPOSE: Paclitaxel, ifosfamide, and cisplatin (TIP) is an established salvage regimen for germ cell tumors (GCT) on the basis of a phase II trial, but efficacy on a large patient cohort including patients with unfavorable risk features and long-term outcomes has not been reported. Herein, we report updated treatment efficacy and long-term follow-up with TIP. PATIENTS AND METHODS: Patients with GCT who received TIP after cisplatin-based chemotherapy were eligible. Favorable response (complete response or partial response with negative tumor markers), overall survival (OS) and progression-free survival (PFS) rates, relapse, and toxicity were determined. Disease was reclassified according to the International Prognostic Factor Study Group (IPFSG) score. RESULTS: Of the 104 patients, 87 had favorable risk factors and 17 had at least one unfavorable factor by Memorial Sloan Kettering Cancer Center (MSKCC) criteria. Ten patients were treated for a second gonadal primary GCT. With a median follow-up of 8.9 years, the 5-year PFS and OS rates were 66% (95% CI, 55 to 74) and 69% (95% CI, 59 to 77), respectively. Among 87 patients with favorable-risk disease, 69 (79%) achieved a favorable response with 5-year PFS and OS rates of 67% (95% CI, 56 to 76) and 72% (95% CI, 61 to 80), respectively. Among 17 patients with MSKCC unfavorable-risk disease, 13 (76%) achieved a favorable response with 5-year PFS and OS rates of 59% (95% CI, 33 to 78) and 56% (95% CI, 28 to 76), respectively. After IPFSG reclassification, 5-year PFS and OS rates for patients with ≤intermediate-risk disease were 75% (95% CI, 50 to 89) and 73% (95% CI, 55 to 85), respectively. CONCLUSION: TIP is an effective second-line regimen for patients with GCT. Similar outcomes were observed in patients with favorable- and unfavorable-risk disease. The randomized TIGER trial (ClinicalTrials.gov identifier: NCT02375204 ) comparing TIP with high-dose chemotherapy will determine the optimal second-line treatment approach.


  • Open Access

    Data from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling

    by Sizhi Paul Gao, Amber J. Kiliti, Kai Zhang, Naresh Vasani, Ninghui Mao, Emmet Jordan, Hannah C. Wise, Tripti Shrestha Bhattarai, Wenhuo Hu, Madeline Dorso, et al.

    Mutational activation of the PI3K/AKT pathway is among the most common pro-oncogenic events in human cancers. The clinical utility of PI3K and AKT inhibitors has, however, been modest to date. Here, we used CRISPR-mediated gene editing to study the biological consequences of AKT1 E17K mutation by developing an AKT1 E17K–mutant isogenic system in a TP53-null background. AKT1 E17K expression under the control of its endogenous promoter enhanced cell growth and colony formation, but had a paradoxical inhibitory effect on cell migration and invasion. The mechanistic basis by which activated AKT1 inhibited cell migration and invasion was increased E-cadherin expression mediated by suppression of ZEB1 transcription via altered β-catenin subcellular localization. This phenotypic effect was AKT1-specific, as AKT2 activation had the opposite effect, a reduction in E-cadherin expression. Consistent with the opposing effects of AKT1 and AKT2 activation on E-cadherin expression, a pro-migratory effect of AKT1 activation was not observed in breast cancer cells with PTEN loss or expression of an activating PIK3CA mutation, alterations which induce the activation of both AKT isoforms. The results suggest that the use of AKT inhibitors in patients with breast cancer could paradoxically accelerate metastatic progression in some genetic contexts and may explain the frequent coselection for CDH1 mutations in AKT1-mutated breast tumors.Implications:AKT1 E17K mutation in breast cancer impairs migration/invasiveness via sequestration of β-catenin to the cell membrane leading to decreased ZEB1 transcription, resulting in increased E-cadherin expression and a reversal of epithelial–mesenchymal transition.

  • Open Access

    Supplementary Figures 1-12, Supplementary Tables 1-3 from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling

    by Sizhi Paul Gao, Amber J. Kiliti, Kai Zhang, Naresh Vasani, Ninghui Mao, Emmet Jordan, Hannah C. Wise, Tripti Shrestha Bhattarai, Wenhuo Hu, Madeline Dorso, et al.

    S1. Generation of MCF-10A isogenic cells via TP53 knockout and AKT1 E17K knock-in. S2. Frequent co-occurrence of AKT1, TP53 and CDH1 mutations in breast cancers. S3. TP53 CRISPR knockout in MCF-10A cells. S4. Phosphorylation of the AKT1 effector PRAS40 was AKT-dependent in MCF-10A p53ko/E17K cells. S5. Immunofluorescence using a pT308 specific AKT1 antibody of MCF-10A cells following lentiviral infection with V5 tagged (V5 tag) wildtype (WT) or E17K mutant AKT1. S6. Knock-in of the AKT1 E17K mutation did not enhance sensitivity to the pan-AKT kinase inhibitor AZD5363 or the allosteric pan-AKT inhibitor MK2206 in 2Dculture conditions. S7. Survey of previously postulated mechanisms for AKT1-mediated inhibition of cell migration in breast cancer cells. S8. CDH1 promoter methylation status in the MCF-10A isogenic cells. S9. β-catenin interacts with the kinase domain of AKT1. S10. Expression of AKT1 E17K decreased phosphorylation of AKT2 in MCF-10A cells. S11. AKT2 knockdown induces E-cadherin expression in MCF-10A p53ko cells. S12. Model of the mechanism of paradoxical inhibition of cell migration by activated AKT1. Table S1. List of oligonucleotide sequences Table S2. List of antibodies Table S3. List of plasmids

  • Open Access

    Supplementary Figures 1-12, Supplementary Tables 1-3 from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling

    by Sizhi Paul Gao, Amber J. Kiliti, Kai Zhang, Naresh Vasani, Ninghui Mao, Emmet Jordan, Hannah C. Wise, Tripti Shrestha Bhattarai, Wenhuo Hu, Madeline Dorso, et al.

    S1. Generation of MCF-10A isogenic cells via TP53 knockout and AKT1 E17K knock-in. S2. Frequent co-occurrence of AKT1, TP53 and CDH1 mutations in breast cancers. S3. TP53 CRISPR knockout in MCF-10A cells. S4. Phosphorylation of the AKT1 effector PRAS40 was AKT-dependent in MCF-10A p53ko/E17K cells. S5. Immunofluorescence using a pT308 specific AKT1 antibody of MCF-10A cells following lentiviral infection with V5 tagged (V5 tag) wildtype (WT) or E17K mutant AKT1. S6. Knock-in of the AKT1 E17K mutation did not enhance sensitivity to the pan-AKT kinase inhibitor AZD5363 or the allosteric pan-AKT inhibitor MK2206 in 2Dculture conditions. S7. Survey of previously postulated mechanisms for AKT1-mediated inhibition of cell migration in breast cancer cells. S8. CDH1 promoter methylation status in the MCF-10A isogenic cells. S9. β-catenin interacts with the kinase domain of AKT1. S10. Expression of AKT1 E17K decreased phosphorylation of AKT2 in MCF-10A cells. S11. AKT2 knockdown induces E-cadherin expression in MCF-10A p53ko cells. S12. Model of the mechanism of paradoxical inhibition of cell migration by activated AKT1. Table S1. List of oligonucleotide sequences Table S2. List of antibodies Table S3. List of plasmids